Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Recommendations on prevention and screening for colorectal cancer in Hong Kong.

Lam TH, Wong KH, Chan KK, Chan MC, Chao DV, Cheung AN, Fan CY, Ho J, Hui EP, Lam KO, Law CK, Law WL, Loong HH, Ngan RK, Tsang TH, Wong MC, Yeung RM, Ying AC, Ching R.

Hong Kong Med J. 2018 Oct;24(5):521-526. doi: 10.12809/hkmj177095.

2.

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer.

Loong HH, Kwan SS, Mok TS, Lau YM.

Curr Treat Options Oncol. 2018 Sep 29;19(11):58. doi: 10.1007/s11864-018-0570-9. Review.

PMID:
30267319
3.

Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial.

Chan ATC, Hui EP, Ngan RKC, Tung SY, Cheng ACK, Ng WT, Lee VHF, Ma BBY, Cheng HC, Wong FCS, Loong HHF, Tong M, Poon DMC, Ahuja AT, King AD, Wang K, Mo F, Zee BCY, Chan KCA, Lo YMD.

J Clin Oncol. 2018 Jul 10:JCO2018777847. doi: 10.1200/JCO.2018.77.7847. [Epub ahead of print]

PMID:
29989858
4.

Optimal management of desmoid fibromatosis.

Loong HH.

Hong Kong Med J. 2018 Jun;24(3):316. doi: 10.12809/hkmj187250. No abstract available.

PMID:
29926797
5.

Recommendations on prevention and screening for breast cancer in Hong Kong.

Lam TH, Wong KH, Chan KK, Chan MC, Chao DV, Cheung AN, Fan CY, Ho J, Hui EP, Lam KO, Law CK, Law WL, Loong HH, Ngan RK, Tsang TH, Wong MC, Yeung RM, Ying AC, Ching R.

Hong Kong Med J. 2018 Jun;24(3):298-306. doi: 10.12809/hkmj177037.

6.

Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.

Loong HH, Raymond VM, Shiotsu Y, Chua DTT, Teo PML, Yung T, Skrzypczak S, Lanman RB, Mok TSK.

Clin Lung Cancer. 2018 Sep;19(5):e601-e608. doi: 10.1016/j.cllc.2018.04.022. Epub 2018 May 7.

PMID:
29807856
7.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056.

PMID:
29788429
8.

A feasibility study on using tablet personal computers for self-reported symptom assessment in newly diagnosed lung cancer patients.

Tang FWK, Chan CWH, Choy YP, Loong HHF, Chow KM, So WKW.

Int J Nurs Pract. 2018 Aug;24(4):e12658. doi: 10.1111/ijn.12658. Epub 2018 Apr 11.

PMID:
29642280
9.

Adherence to the World Cancer Research Fund/American Institute for Cancer Research Guideline Is Associated With Better Health-Related Quality of Life Among Chinese Patients With Breast Cancer.

Lei YY, Ho SC, Cheng A, Kwok C, Lee CI, Cheung KL, Lee R, Loong HHF, He YQ, Yeo W.

J Natl Compr Canc Netw. 2018 Mar;16(3):275-285. doi: 10.6004/jnccn.2017.7202.

PMID:
29523666
10.

Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy.

Yeo W, Mo FK, Pang E, Suen JJ, Koh J, Yip CH, Yip CC, Li L, Loong HH, Liem GS.

Cancer Manag Res. 2018 Feb 22;10:383-389. doi: 10.2147/CMAR.S149983. eCollection 2018.

11.

Overview of current systemic management of EGFR-mutant NSCLC.

Hsu WH, Yang JC, Mok TS, Loong HH.

Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9. doi: 10.1093/annonc/mdx702.

PMID:
29462253
12.

PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.

To KKW, Wu WKK, Loong HHF.

Eur J Pharmacol. 2018 Mar 15;823:19-26. doi: 10.1016/j.ejphar.2018.01.036. Epub 2018 Jan 31.

PMID:
29378193
13.

Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas.

Loong HH, Wong KH, Tse T.

ESMO Open. 2018 Jan 3;3(Suppl 1):e000293. doi: 10.1136/esmoopen-2017-000293. eCollection 2018.

14.

Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study.

Hui EP, Ma BBY, Loong HHF, Mo F, Li L, King AD, Wang K, Ahuja AT, Chan CML, Hui CWC, Wong CH, Chan ATC.

Clin Cancer Res. 2018 Mar 1;24(5):1030-1037. doi: 10.1158/1078-0432.CCR-17-1667. Epub 2018 Jan 4.

PMID:
29301831
15.

Fertility preservation in young cancer patients as a springboard to address the needs of this unique population.

Loong HH.

Hong Kong Med J. 2017 Dec;23(6):552-3. doi: 10.12809/hkmj175072. No abstract available.

16.

Frameless stereotactic radiosurgery for brain metastases: a review of outcomes and prognostic scores evaluation.

Mok ST, Kam MK, Tsang WK, Poon DM, Loong HH, Yeung WM, Yeung TY, Yu J, Wong CK.

Hong Kong Med J. 2017 Dec;23(6):599-608. doi: 10.12809/hkmj166138. Epub 2017 Nov 10.

17.

Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.

Hsieh SY, Chan DT, Kam MK, Loong HH, Tsang WK, Poon DM, Ng SC, Poon WS.

Hong Kong Med J. 2017 Dec;23(6):594-8. doi: 10.12809/hkmj165002. Epub 2017 Aug 11.

18.

Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.

Tong CWS, Wu WKK, Loong HHF, Cho WCS, To KKW.

Cancer Lett. 2017 Oct 1;405:100-110. doi: 10.1016/j.canlet.2017.07.023. Epub 2017 Jul 31. Review.

PMID:
28774798
19.

Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy.

Yeo W, Mo FKF, Pang E, Suen JJS, Koh J, Loong HHF, Yip CCH, Ng RYW, Yip CHW, Tang NLS, Liem GS.

BMC Womens Health. 2017 Jul 27;17(1):55. doi: 10.1186/s12905-017-0409-8.

20.

Ten-year review of survival and management of malignant glioma in Hong Kong.

Chan DT, Hsieh SY, Lau CK, Kam MK, Loong HH, Tsang WK, Poon DM, Poon WS.

Hong Kong Med J. 2017 Apr;23(2):134-9. doi: 10.12809/hkmj164879. Epub 2016 Dec 2.

21.

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR.

J Clin Oncol. 2016 Sep 10;34(26):3166-74. doi: 10.1200/JCO.2016.67.6346. Epub 2016 Jul 25.

22.

Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg).

Choy CT, Wong CH, Loong HHF.

J Neurooncol. 2016 Sep;129(3):579-581. doi: 10.1007/s11060-016-2209-7. Epub 2016 Jul 18. No abstract available.

PMID:
27431689
23.

Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies.

Loong HH, Chan AC, Wong AC.

J Cancer. 2016 Jan 8;7(3):268-75. doi: 10.7150/jca.12986. eCollection 2016. Review.

24.

Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?

Mok TS, Loong HH.

Lancet. 2016 Apr 9;387(10027):1488-90. doi: 10.1016/S0140-6736(15)01308-2. Epub 2015 Dec 19. No abstract available.

PMID:
26712085
25.

Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.

Hui EP, Ma BB, Chan KC, Chan CM, Wong CS, To KF, Chan AW, Tung SY, Ng WT, Cheng AC, Lee VH, Chan SL, Loong HH, Kam MK, Leung SF, Ho R, Mo F, Ngan RK, Chan AT.

Cancer. 2015 Aug 15;121(16):2720-9. doi: 10.1002/cncr.29413. Epub 2015 May 6.

26.

Crizotinib in the management of advanced-stage non-small-cell lung cancer.

Loong HH, Mok K, Leung LK, Mok TS.

Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314. Review.

PMID:
25757678
27.

Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.

Loong HH, Winquist E, Waldron J, Chen EX, Kim J, Palma D, Read N, Razak AR, Diaz-Padilla I, Chan K, Bayley A, Hossain M, Wang L, Chin S, Siu LL, Hope A.

Eur J Cancer. 2014 Sep;50(13):2263-70. doi: 10.1016/j.ejca.2014.05.021. Epub 2014 Jun 19.

PMID:
24953566
28.

A REVELation in non-small-cell lung cancer treatment?

Mok TS, Loong HH.

Lancet. 2014 Aug 23;384(9944):640-2. doi: 10.1016/S0140-6736(14)60895-3. Epub 2014 Jun 2. No abstract available.

PMID:
24933331
29.

Lung cancer: dropping bars or rising hoops--phase III outcomes of NSCLC.

Loong HH, Mok TS.

Nat Rev Clin Oncol. 2014 Jul;11(7):381-2. doi: 10.1038/nrclinonc.2014.91. Epub 2014 May 20.

PMID:
24840075
30.

Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.

Loong HH, Yeo W.

Onco Targets Ther. 2014 Apr 16;7:575-85. doi: 10.2147/OTT.S46019. eCollection 2014. Review.

31.

Controversies in the systemic treatment of nasopharyngeal carcinoma.

Loong HH, Chan AT.

Oral Oncol. 2014 Sep;50(9):785-90. doi: 10.1016/j.oraloncology.2014.01.010. Epub 2014 Feb 17.

PMID:
24556422
32.

Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.

Wong CH, Loong HH, Hui CW, Lau CP, Hui EP, Ma BB, Chan AT.

Invest New Drugs. 2013 Dec;31(6):1399-408. doi: 10.1007/s10637-013-0007-z. Epub 2013 Aug 24.

PMID:
23975511
33.

Selecting the best drugs for phase I clinical development and beyond.

Loong HH, Siu LL.

Am Soc Clin Oncol Educ Book. 2013:469-73. doi: 10.1200/EdBook_AM.2013.33.469. Review.

34.

Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK, Chan AT.

Radiother Oncol. 2012 Sep;104(3):300-4. doi: 10.1016/j.radonc.2011.12.022. Epub 2012 Jan 31.

PMID:
22300609
35.

Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma.

Chan SL, Mo FK, Wong VW, Liem GS, Wong GL, Chan VT, Poon DM, Loong HH, Yeo W, Chan AT, Mok TS, Chan HL.

Liver Int. 2012 Feb;32(2):271-8. doi: 10.1111/j.1478-3231.2011.02634.x. Epub 2011 Aug 31.

PMID:
22098536
36.

Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation.

Hui EP, Ma BB, King AD, Mo F, Chan SL, Kam MK, Loong HH, Ahuja AT, Zee BC, Chan AT.

Ann Oncol. 2011 Jun;22(6):1280-7. doi: 10.1093/annonc/mdq629. Epub 2011 Feb 11.

PMID:
21317222
37.

Personalized medicine for non-small-cell lung cancer.

Mok TS, Zhou Q, Leung L, Loong HH.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1601-11. doi: 10.1586/era.10.76. Review.

PMID:
20942631
38.

Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.

Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS.

J Clin Oncol. 2010 Apr 1;28(10):1660-5. doi: 10.1200/JCO.2009.26.2675. Epub 2010 Mar 1.

PMID:
20194845
39.

Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer.

Loong HH, Ma BB, Chan AT.

J Oncol. 2009;2009:967920. doi: 10.1155/2009/967920. Epub 2009 Apr 9.

40.
41.

Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.

Loong HH, Ma BB, Chan AT.

Hematol Oncol Clin North Am. 2008 Dec;22(6):1267-78, x. doi: 10.1016/j.hoc.2008.08.012. Review.

PMID:
19010273
42.

Novel agents in the frontline management of multiple myeloma.

Loong HH.

Hematol Oncol Stem Cell Ther. 2008 Oct-Dec;1(4):201-9. Review.

43.

Gastro-intestinal stromal tumours: a review of current management options.

Loong HH.

Hong Kong Med J. 2007 Feb;13(1):61-5. Review.

44.

A not-so-uncommon presentation of an uncommon disease: nasal natural killer/T-cell lymphoma.

Loong HH, Cheung CY, Lam YK.

Hong Kong Med J. 2006 Dec;12(6):470-2.

Supplemental Content

Loading ...
Support Center